Enhanced Liver Fibrosis (ELF) ELF
Synonyms |
|||||||||
Allscripts (AEHR) Order Name |
Enhanced Liver Fibrosis (ELF) |
||||||||
Sunrise Clinical Manager (SCM) Order Name |
Enhanced Liver Fibrosis (ELF) |
||||||||
EPIC Order Name |
|||||||||
Clinical Info |
Non-invasive test that provides a simple, unitless numeric score that is generated via an algorithm for use in advanced liver fibrosis. It is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to nonalcoholic steatohepatitis (NASH), now called metabolic dysfunction-associated steatohepatitis (MASH), to assess the likelihood of progression to cirrhosis and liver-related clinical events |
||||||||
Specimen Type |
Blood |
||||||||
Specimen Volume |
2.5 mL serum ( 1mL min) |
||||||||
Container |
Gold Top Tube or Red Top Tube |
||||||||
Collection Instructions |
Specimen: 2.5 mL serum (1mL min) |
||||||||
Transport Instructions |
Refrigerated |
||||||||
Specimen Stability |
2 Days Room Temperature |
||||||||
Methodology |
Direct chemiluminometric |
||||||||
Days Performed |
TAT: 4-7 Days |
||||||||
Performing Laboratory |
LabCorp |
||||||||
CPT |
81517 |
||||||||
PDM |
245342 |
||||||||
Result InterpretationELF™ Score Interpretation: Risk cut-offs to assess the likelihood of progression to cirrhosis and liver-related clinical events within 3.9 years following baseline ELF score (IQR: 14.0-22.4 months):5
|
|||||||||
Forms |
|
